Ipamorelin

Research-Documented Benefits

• Selective GH Release — Ipamorelin is noted for its high selectivity in stimulating GH secretion without significant increases in cortisol, prolactin, or ACTH levels.
• Favorable Safety Profile — Among growth hormone secretagogues, ipamorelin demonstrates one of the most targeted activity profiles in published research.
• Bone Density — Studies in ovariectomized rats demonstrate improved bone mineral content and mechanical strength with ipamorelin treatment.
• Body Composition — Research shows dose-dependent increases in GH release, supporting lean tissue anabolism and metabolic rate enhancement.
• GI Motility — Documented prokinetic effects on gastrointestinal smooth muscle, with potential applications in post-operative ileus research.

Mechanism of Action

Ipamorelin (Aib-His-D-2Nal-D-Phe-Lys-NH2) is a pentapeptide growth hormone secretagogue that selectively activates the ghrelin/growth hormone secretagogue receptor (GHS-R1a).

Primary Pathways

• GHS-R1a Selective Agonism — Unlike GHRP-6 and GHRP-2, ipamorelin demonstrates remarkable selectivity, stimulating GH release without significant activation of ACTH, cortisol, or prolactin secretion pathways.
• Calcium Signaling — Receptor binding triggers phospholipase C activation and inositol triphosphate-mediated calcium release from intracellular stores in somatotroph cells.
• Dose-Linear GH Response — Studies show a clean dose-response relationship for GH release, making ipamorelin a reliable research tool for GH-axis investigation.
• GI Motility — Activates GHS-R1a receptors in the enteric nervous system, promoting coordinated gastrointestinal smooth muscle contractions (prokinetic effect).

Ipamorelin's selectivity profile—stimulating GH without cortisol, prolactin, or appetite effects—makes it one of the cleanest GH secretagogues available for research applications.

Research Protocol Guidelines

All protocols described are for in vitro and in vivo research purposes only. Not for human use.

Reconstitution

Reconstitute lyophilized ipamorelin with bacteriostatic water. For a 2 mg vial, adding 2 mL yields 1 mg/mL.

Research Dosing (Preclinical Literature)

• GH secretion studies: 1 mcg/kg subcutaneously, administered 2-3 times daily at consistent intervals
• Dose-response studies: 0.01-1 mg/kg range demonstrating dose-linear GH release in rodent models
• Combination protocols: Often co-administered with CJC-1295 (no DAC) or sermorelin for synergistic GH release research
• GI motility: 0.01-0.1 mg/kg IV in post-operative ileus research models

Storage

Store lyophilized form at -20°C. Reconstituted solution at 2-8°C, use within 21 days. Ipamorelin is relatively stable in reconstituted form.

Safety & Handling Information

For research use only. Not intended for human or veterinary diagnostic or therapeutic use.

Storage Requirements

• Lyophilized: -20°C, desiccated
• Reconstituted: 2-8°C, use within 21 days

Preclinical Safety Profile

Ipamorelin demonstrates one of the most favorable safety profiles among GH secretagogues. Phase II clinical studies report mild, transient adverse events consistent with the GH secretagogue class.

Known Considerations

• Unlike GHRP-6, ipamorelin does not significantly elevate cortisol, prolactin, or ACTH at standard research doses
• GH/IGF-1 axis stimulation considerations apply as with all secretagogues
• No reported appetite stimulation at standard doses (unlike ghrelin-mimetic secretagogues)
• Mild GI motility effects may confound studies of gastrointestinal function

Handling

Standard laboratory PPE. Aseptic technique for reconstitution and administration.

Frequently Asked Questions